Related Experiment Video
Updated: Mar 6, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites
Neeta K Venepalli1, Mary V Modayil1, Stephanie A Berg1
1Neeta K Venepalli, Tad D Nair, Mayur Parepally, Priyanka Rajaram, Yue Huang, Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL 60612, United States.
Insights
Hispanic patients with hepatocellular carcinoma (HCC) face higher risks of metabolic conditions like nonalcoholic steatohepatitis (NASH) and experience shorter overall survival (OS). This highlights disparities in HCC outcomes among racial groups.
Area of Science:
- Hepatology
- Oncology
- Epidemiology
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Understanding racial and ethnic disparities in HCC is crucial for targeted interventions.
- Previous research indicates variations in HCC characteristics across different populations.
Purpose of the Study:
- To compare the clinical and demographic features of hepatocellular carcinoma (HCC) in Hispanic patients against those in African American and White patients.
- To identify specific risk factors and comorbidities associated with HCC in the Hispanic population.
Main Methods:
- Retrospective analysis of 195 patients diagnosed with HCC between 2005 and 2011 at an urban tertiary medical center.
- Data collection included demographics, comorbidities, liver disease characteristics, tumor parameters, treatment, and overall survival (OS).
- Kaplan-Meier method was used for overall survival analyses.
Main Results:
- Hispanic patients (22.6%) were more likely to have diabetes, hyperlipidemia, nonalcoholic steatohepatitis (NASH), and end-stage renal disease compared to African American (31.2%) and White (46.2%) patients.
- Hispanic patients had a lower incidence of hepatitis C virus (HCV) and smoking history.
- Hispanic patients exhibited higher MELD scores, ascites, and encephalopathy, and experienced shorter overall survival (OS) than other racial groups.
Conclusions:
- Hispanic patients with HCC demonstrate a higher prevalence of modifiable metabolic risk factors, including NASH.
- These patients experience significantly shorter overall survival (OS) compared to African American and White patients.
- Findings underscore the need for focused strategies to address metabolic health and improve HCC outcomes in Hispanic populations.
Aim:
To compare features of hepatocellular carcinoma (HCC) in Hispanics to those of African Americans and Whites.
Methods:
Patients treated for HCC at an urban tertiary medical center from 2005 to 2011 were identified from a tumor registry. Data were collected retrospectively, including demographics, comorbidities, liver disease characteristics, tumor parameters, treatment, and survival (OS) outcomes. OS analyses were performed using Kaplan-Meier method.
Results:
One hundred and ninety-five patients with HCC were identified: 80.5% were male, and 22% were age 65 or older. Mean age at HCC diagnosis was 59.7 ± 9.8 years. Sixty-one point five percent of patients had Medicare or Medicaid; 4.1% were uninsured. Compared to African American (31.2%) and White (46.2%) patients, Hispanic patients (22.6%) were more likely to have diabetes (P = 0.0019), hyperlipidemia (P = 0.0001), nonalcoholic steatohepatitis (NASH) (P = 0.0021), end stage renal disease (P = 0.0057), and less likely to have hepatitis C virus (P < 0.0001) or a smoking history (P < 0.0001). Compared to African Americans, Hispanics were more likely to meet criteria for metabolic syndrome (P = 0.0491), had higher median MELD scores (P = 0.0159), ascites (P = 0.008), and encephalopathy (P = 0.0087). Hispanic patients with HCC had shorter OS than the other racial groups (P = 0.020), despite similarities in HCC parameters and treatment.
Conclusion:
In conclusion, Hispanic patients with HCC have higher incidence of modifiable metabolic risk factors including NASH, and shorter OS than African American and White patients.
More Related Videos
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Stereotypes, Prejudice, and Discrimination
Surveys
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Test for Homogeneity

